Study to Evaluate Optimized Retreatment and Prolonged Therapy With Bortezomib

NCT01910987 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: bortezomib (optimized retreatment)
DRUG: dexamethasone (optimized retreatment)
DRUG: bortezomib (standard retreatment)
DRUG: dexamethasone (standard retreatment)

Sponsor

Janssen-Cilag International NV